https://www.selleckchem.com/products/h3b-6527.html
BACKGROUND International guidelines advise universal beta blocker therapy as either a class I (symptomatic or QTc 470 ms) or class II recommendation (asymptomatic and QTc less then 470 ms) in the treatment of Long QT Syndrome (LQTS). OBJECTIVE This study sought to evaluate the outcomes of a highly selected cohort of patients with LQTS managed with an observation only (intentional non-treatment) strategy. METHODS The cohort was derived using a comprehensive retrospective registry of patients with LQTS. Clinical phenotype and genoty
Like
Comment
Share
